The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

Over the past year, the question has been coming in from everywhere – from my patients and family members, from colleagues ...

French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Operator: Good afternoon, and welcome to AbCellera’s Q3 2024 Business Update Conference Call. My name is Tamiya, and I will ...

Good afternoon, and welcome to AbCellera's Q3 2024 business update conference call. My name is Tamia, and I will facilitate ...

The analyst underscored that Dupixent (Dupi), Regeneron's medication for various inflammatory conditions, continues to be one of the most promising product launches in the biopharmaceutical sector.

“Since starting Dupixent, my skin is clearer ... “There are so many factors that have contributed to the way the WNBA is finally getting its due,” she said. “Caitlin’s success, and ...